Table 5

Relation between marker (serum chromogranin A) and patient characteristics [181] (note that missing data were not indicated).

Serum CgA levels, ng/mL


Number

Median

Q1 to Q3

Minimum to maximum

P


Subjects

Controls

50

77.4

57.7 to 99.9

28.2 to 196.3

NSCLC patients

88

70.4

37.9 to 114.6

8.7 to 723.8

0.337

Histotype

Adenocarcinoma

22

59.2

35.2 to 85.6

14.8 to 151.2

Squamous

27

80.0

41.0 to 128.6

14.7 to 386.8

Large cell

10

82.1

33.7 to 124.0

11.4 to 217.9

0.465

ECOG PS

0

16

37.7

27.2 to 68.6

8.7 to 103.1

1

59

76.3

43.6 to 119.2

13.9 to 429.7

≥2

13

102.8

55.8 to 259.4

32.1 to 723.8

0.0005

Stage

IIIB

29

44.9

29.2 to 85.6

13.9 to 259.4

IV

59

82.5

47.1 to 119.2

8.7 to 723.8

0.043


CgA: chromogranin A; ECOG PS: Eastern Cooperative Oncology Group performance status; NSCLC: non-small cell lung cancer; Q1 to Q3: interquartile range.

Altman et al. BMC Medicine 2012 10:51   doi:10.1186/1741-7015-10-51

Open Data